Dyne Therapeutics Inc
NASDAQ:DYN
Income Statement
Earnings Waterfall
Dyne Therapeutics Inc
Income Statement
Dyne Therapeutics Inc
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(97)
|
(127)
|
(150)
|
(161)
|
(183)
|
(183)
|
(171)
|
(181)
|
(195)
|
(215)
|
(242)
|
(266)
|
(271)
|
(314)
|
(344)
|
(397)
|
(441)
|
(449)
|
|
| Selling, General & Administrative |
(23)
|
(26)
|
(29)
|
(30)
|
(30)
|
(31)
|
(28)
|
(29)
|
(30)
|
(30)
|
(31)
|
(48)
|
(50)
|
(56)
|
(62)
|
(54)
|
(61)
|
(64)
|
|
| Research & Development |
(74)
|
(101)
|
(121)
|
(131)
|
(154)
|
(152)
|
(143)
|
(152)
|
(165)
|
(185)
|
(211)
|
(218)
|
(221)
|
(258)
|
(281)
|
(343)
|
(380)
|
(385)
|
|
| Operating Income |
(97)
N/A
|
(127)
-30%
|
(150)
-18%
|
(161)
-7%
|
(183)
-14%
|
(183)
+0%
|
(171)
+6%
|
(181)
-6%
|
(195)
-8%
|
(215)
-10%
|
(242)
-13%
|
(266)
-10%
|
(271)
-2%
|
(314)
-16%
|
(344)
-9%
|
(397)
-15%
|
(441)
-11%
|
(449)
-2%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
0
|
1
|
1
|
1
|
1
|
2
|
3
|
4
|
6
|
7
|
8
|
9
|
14
|
21
|
27
|
31
|
30
|
27
|
|
| Total Other Income |
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(2)
|
(1)
|
|
| Pre-Tax Income |
(98)
N/A
|
(126)
-29%
|
(149)
-18%
|
(160)
-7%
|
(182)
-14%
|
(181)
+1%
|
(168)
+7%
|
(177)
-5%
|
(189)
-7%
|
(208)
-10%
|
(236)
-13%
|
(257)
-9%
|
(258)
0%
|
(295)
-14%
|
(317)
-8%
|
(367)
-16%
|
(413)
-12%
|
(424)
-3%
|
|
| Net Income | |||||||||||||||||||
| Income from Continuing Operations |
(98)
|
(126)
|
(149)
|
(160)
|
(182)
|
(181)
|
(168)
|
(177)
|
(189)
|
(208)
|
(236)
|
(257)
|
(258)
|
(295)
|
(317)
|
(367)
|
(413)
|
(424)
|
|
| Net Income (Common) |
(98)
N/A
|
(126)
-29%
|
(149)
-18%
|
(160)
-7%
|
(182)
-14%
|
(181)
+1%
|
(168)
+7%
|
(177)
-5%
|
(189)
-7%
|
(208)
-10%
|
(236)
-13%
|
(257)
-9%
|
(258)
0%
|
(295)
-14%
|
(317)
-8%
|
(367)
-16%
|
(413)
-12%
|
(424)
-3%
|
|
| EPS (Diluted) |
-1.9
N/A
|
-2.45
-29%
|
-2.93
-20%
|
-3.1
-6%
|
-3.53
-14%
|
-3.5
+1%
|
-3.23
+8%
|
-3.13
+3%
|
-3.16
-1%
|
-3.4
-8%
|
-3.95
-16%
|
-3.17
+20%
|
-2.78
+12%
|
-2.91
-5%
|
-3.37
-16%
|
-3.34
+1%
|
-3.62
-8%
|
-2.98
+18%
|
|